脓毒症患者血浆MMP-3与TIMP-1升高与器官功能障碍及死亡相关
本研究为单中心前瞻性队列研究,纳入按Sepsis-3标准判定的脓毒症危重患者,入ICU时检测血浆MMP-3、MMP-9和TIMP-1浓度,并分析其与休克、ARDS、AKI及30天死亡的关系。结果显示,TIMP-1每对数升高与休克(OR 1.51)、ARDS(OR 1.24)、AKI(OR 1.18)和死亡(OR 1.20)相关;MMP-3每对数升高与休克(OR 1.40)和死亡(OR 1.24)相关;MMP-9与上述结局均无关联。TIMP-1/MMP-3比值升高与休克相关(OR 1.41)。提示TIMP-1和MMP-3可能作为脓毒症新型诊疗生物标志物,值得进一步研究。
要点
- 脓毒症患者入ICU时血浆TIMP-1每对数升高,休克风险OR 1.51(95%CI 1.25–1.83),30天死亡OR 1.20(95%CI 1.05–1.46)。
- 血浆MMP-3每对数升高与休克(OR 1.40,95%CI 1.12–1.75)和30天死亡(OR 1.24,95%CI 1.03–1.48)相关。
- 血浆MMP-9水平与休克、ARDS、AKI及死亡均无关联。
- TIMP-1每对数升高还与ARDS(OR 1.24,95%CI 1.05–1.46)和AKI(OR 1.18,95%CI 1.01–1.38)相关。
- TIMP-1/MMP-3比值升高与休克相关(OR 1.41,95%CI 1.15–1.72,P=0.02)。
适用人群与场景
- 在三级学术医疗中心ICU收治的、按Sepsis-3标准判定的脓毒症危重患者。
诊断标准与关键阈值
- 脓毒症判定采用Sepsis-3标准。
- 入ICU时采血检测血浆MMP-3、MMP-9、TIMP-1浓度及TIMP-1/MMP-3比值。
- 结局表型包括休克、ARDS、AKI及30天死亡。
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:单中心前瞻性队列研究;人群:三级学术医疗中心ICU的脓毒症危重患者(Sepsis-3标准);干预/暴露:入ICU时检测血浆MMP-3、MMP-9、TIMP-1;对照:以生物标志物水平作连续变量行logistic回归。
- TIMP-1每对数升高与休克(OR 1.51,95%CI 1.25–1.83)、ARDS(OR 1.24,95%CI 1.05–1.46)、AKI(OR 1.18,95%CI 1.01–1.38)和死亡(OR 1.20,95%CI 1.05–1.46)相关。
- MMP-3每对数升高与休克(OR 1.40,95%CI 1.12–1.75)和死亡(OR 1.24,95%CI 1.03–1.48)相关。
- MMP-9与休克、ARDS、AKI及死亡均无关联。
- TIMP-1/MMP-3比值升高与休克相关(OR 1.41,95%CI 1.15–1.72,P=0.02)。
证据类型、等级与局限
- 证据类型:单中心前瞻性队列研究。
- 局限:单中心研究;原文未提及样本量;生物标志物关联性分析,尚未验证为决策阈值。
对床旁实践的改变
- 原文提示TIMP-1和MMP-3可能作为脓毒症新兴诊疗生物标志物,值得进一步研究,但尚未提供床旁可用的决策阈值或干预方案。
- 原文未提及适用与不适用人群的排除标准。
- 常见陷阱:不能将本研究的OR值直接用作床旁决策阈值;MMP-9与结局无关联,不应据此解读MMP-9。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Matrix Metalloproteinases (MMP) respond to tissue damage during sepsis. Higher plasma concentrations of MMPs and the tissue-inhibitor of matrix metalloproteinases (TIMP) have been reported in sepsis compared with healthy controls. The objective of this study was to examine if plasma levels of MMP-3, MMP-9, and TIMP-1 associate with mortality and organ dysfunction during sepsis.
METHODS: We conducted a prospective cohort study of critically ill patients with sepsis adjudicated per Sepsis-3 criteria at a tertiary academic medical center. We measured plasma concentrations of MMP-3, MMP-9, and TIMP-1 on intensive care unit admission. We phenotyped the subjects for shock, acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and mortality at 30 days. We used logistic regression to test the associations between the MMPs and TIMP-1 with shock, ARDS, AKI, and mortality.
RESULTS: Higher plasma TIMP-1 levels were associated with shock (odds ratio [OR] 1.51 per log increase [95% CI 1.25, 1.83]), ARDS (OR 1.24 [95% CI 1.05, 1.46]), AKI (OR 1.18 [95% CI 1.01, 1.38]), and mortality (OR 1.20 [95% CI 1.05, 1.46]. Higher plasma MMP-3 concentrations were associated with shock (OR 1.40 [95% CI 1.12, 1.75]) and mortality (OR 1.24 [95% CI 1.03, 1.48]) whereas MMP-9 levels were not associated with outcomes. Higher plasma TIMP-1 to MMP-3 ratios were associated with shock (OR 1.41 [95% CI 1.15, 1.72], P = 0.02).
CONCLUSION: Elevated plasma concentrations of TIMP-1 associate with organ dysfunction and mortality in sepsis. Higher plasma levels of MMP-3 associate with shock and mortality. Plasma MMP and TIMP-1 may warrant further investigation as emerging sepsis theragnostic biomarkers.
参考来源
- Jones TK, Reilly JP, Anderson BJ, et al. Elevated Plasma Levels of Matrix Metalloproteinase-3 and Tissue-Inhibitor of Matrix Metalloproteinases-1 Associate With Organ Dysfunction and Mortality in Sepsis. Shock. 2022. PMID: 34265829. doi:10.1097/SHK.0000000000001833
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。